Discovery Accelerated

BioSymetrics is accelerating early stage drug development by building a more comprehensive view of human health and pharmaceutical research using AI.

NEW Case Study:

Applying Contingent AI to predict targets within the RxRx-19 COVID data set

BioSymetrics is impacting every stage of drug discovery and pharmaceutical research. Roll-over the hot spots below to see how.

TARGET-BASED DRUG DISCOVERY

Applying our ContingentAI framework to clinical data allows for novel gene-disease associations
Our in vivo experimental platform allows us to work in specific genetic contexts, allowing scalable complementation assays
Drug screening leverages our phenotypic barcoding platform, allowing automated lead identification for multi-dimensional phenotype rescue
Predicted off-target effects and toxicity models are used to optimize lead structures

Our target-based approach leverages computational and experimental processes to better predict in vivo efficacy and off-target effects.

PHENOTYPE-BASED DRUG DISCOVERY

Applying our Contingent-AI™ framework to clinical data allows for novel gene-disease associations
Our in vivo experimental platform allows us to work in specific genetic contexts, allowing scalable complementation assays
Drug screening leverages our phenotypic barcoding platform, allowing automated lead identification for multi-dimensional phenotype rescue
Predicted off-target effects and toxicity models are used to optimize lead structures

The Contingent-AI™ computational framework begins with phenotypic screens as input, and predicts molecular mechanism, shortening timelines for target/mechanism identification.

COMPUTATIONAL

Contingent A.I.™

  • Dynamically reduces bias from experimental datasets, including from high-content screening
  • Automated preprocessing of disparate data types (e.g. HCS, proteomics, genomics / transcriptomics) and data sources for faster discovery

EXPERIMENTAL

In Vivo Phenotypic Barcoding

  • We leverage a multi-dimensional “barcode” of in vivo phenotypic characteristics predictive of potential clinical applications and toxicity

AI DRUG DISCOVERY

BioSymetrics Combines Experimental and Machine Learning Methods to Enrich Target-Based Drug Discovery and Shorten Timelines for Phenotype-Based Drug Discovery

Life science companies tend focus on machine learning, ignoring the impact of the decisions they made in collecting and processing their data.

BioSymetrics has built a fundamentally different approach to Data Science, optimizing every step of the pharmaceutical research process using Contingent-AI™.

Pre-processing Artificial Intelligence

The result: less time spent in data processing, easier data integration, more accurate results for diagnostics and drug discovery, as well as truly autonomous capabilities for precision medicine

BioSymetrics Overview (4min)
Webinar – Predicting MOA using AI (Archive).
WATCH THE WEBINAR ARCHIVE
Explore work we are doing in drug repurposing.
COVID-19 INTERACTIVE BLOG

“BioSymetrics is unique in its focus on efficient pre-processing, enabling more transparent model building in biomedicine. We’re excited to be users of the platform.”

Dr. Eric SchadtFounder and CEO, Sema4

“BioSymetrics has supported us in a variety of projects in different settings. In health insurance, their platform saved us months of man hours and approximately $6.4 million (£5-million) annually … the use of Augusta enabled the company to drive faster, more accurate and meaningful innovation.”

Matt HickeyFounder and CEO, Intacare
Recent Blog Posts
August 19, 2020 in Corporate News, Drug Discovery, Industry News, Press Release, Press Release

BioSymetrics Collaborates with Janssen and Sema4 to Predict the Onset of COVID-19

NEW YORK, August 19, 2020 (PR NEWSWIRE) – BioSymetrics, a biomedical artificial intelligence company that provides clinical insights and helps researchers develop drugs with greater speed and precision, announces collaboration…
Read More
August 13, 2020 in Corporate News, Drug Discovery, Press Release

BioSymetrics Joins Accenture’s INTIENT Network

"BioSymetrics’ participation in the ecosystem and integration with Accenture's INTIENT network will give scientists another important capability to help interpret the growing volumes of rich and diverse data that is…
Read More
June 23, 2020 in Blog Post, Drug Discovery

Explore Drug Effects Against SARS-CoV-2 Phenotypic Screening in the Interactive Blog

Remdesivir shows strong, dose-dependent therapeutic effects against SARS-CoV-2 in phenotypic screening. Our interactive COVID-19 blog lets you explore the data.
Read More
June 16, 2020 in Case Study, Drug Discovery, Media, Video

Predicting Mechanism of Action Using AI – Webinar

In this webinar, Mikalai Malinouski Ph.D.demonstrated how BioSymetrics uses AI in the prediction of mechanism of action (MOA), and provided a an example of how machine learning workflows can benefit…
Read More